Literature DB >> 10922489

Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.

K Bandoh1, J Aoki, A Taira, M Tsujimoto, H Arai, K Inoue.   

Abstract

We examined the structure-activity relationship of cloned lysophosphatidic acid (LPA) receptors (endothelial cell differentiation gene (EDG) 2, EDG4, and EDG7) by measuring [Ca(2+)](i) in Sf9 insect cells expressing each receptor using LPA with various acyl chains bound at either the sn-1 or the sn-2 position of the glycerol backbone. For EDG7 the highest reactivity was observed with LPA with Delta9-unsaturated fatty acid (oleic (18:1), linoleic (18:2), and linolenic (18:3)) at sn-2 followed by 2-palmitoleoyl (16:1) and 2-arachidonoyl (20:4) LPA. In contrast, EDG2 and EDG4 showed broad ligand specificities, although EDG2 and EDG4 discriminated between 14:0 (myristoyl) and 16:0 (palmitoyl), and 12:0 (lauroyl) and 14:0 LPAs, respectively. EDG7 recognizes the cis double bond at the Delta9 position of octadecanoyl residues, since 2-elaidoyl (18:1, trans) and 2-petroselinoyl (18:1, cis-Delta12) LPA were poor ligands for EDG7. In conclusion, the present study demonstrates that each LPA receptor can be activated differentially by the LPA species.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10922489     DOI: 10.1016/s0014-5793(00)01827-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  70 in total

1.  Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis.

Authors:  Adrienne E Dubin; Deron R Herr; Jerold Chun
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 2.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 3.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

4.  Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Sandra Grès; Jean Sébastien Saulnier-Blache; Jean-Claude Bordet; Julien Guglielmi; Philippe Clézardin; Olivier Peyruchaud
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

Authors:  Spencer B Jones; Lance A Pfeifer; Thomas J Bleisch; Thomas J Beauchamp; Jim D Durbin; V Joseph Klimkowski; Norman E Hughes; Christopher J Rito; Yen Dao; Joseph M Gruber; Hai Bui; Mark G Chambers; Srinivasan Chandrasekhar; Chaohua Lin; Denis J McCann; Daniel R Mudra; Jennifer L Oskins; Craig A Swearingen; Kannan Thirunavukkarasu; Bryan H Norman
Journal:  ACS Med Chem Lett       Date:  2016-08-02       Impact factor: 4.345

Review 6.  Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.

Authors:  Glenn D Prestwich; Joanna Gajewiak; Honglu Zhang; Xiaoyu Xu; Guanghui Yang; Monica Serban
Journal:  Biochim Biophys Acta       Date:  2008-04-08

7.  Lack of stereospecificity in lysophosphatidic acid enantiomer-induced calcium mobilization in human erythroleukemia cells.

Authors:  Ulrika K Nilsson; Rolf G G Andersson; Johan Ekeroth; Elisabeth C Hallin; Peter Konradsson; Jan Lindberg; Samuel P S Svensson
Journal:  Lipids       Date:  2003-10       Impact factor: 1.880

Review 8.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  A novel approach for measuring sphingosine-1-phosphate and lysophosphatidic acid binding to carrier proteins using monoclonal antibodies and the Kinetic Exclusion Assay.

Authors:  Jonathan K Fleming; Thomas R Glass; Steve J Lackie; Jonathan M Wojciak
Journal:  J Lipid Res       Date:  2016-07-21       Impact factor: 5.922

10.  NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.

Authors:  Yong-Seok Oh; Nam Won Jo; Jung Woong Choi; Hyeon Soo Kim; Sang-Won Seo; Kyung-Ok Kang; Jong-Ik Hwang; Kyun Heo; Sun-Hee Kim; Yun-Hee Kim; In-Hoo Kim; Jae Ho Kim; Yoshiko Banno; Sung Ho Ryu; Pann-Ghill Suh
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.